SAMSHA recommends use of Buprenorpine mono product when there is an allergy or other adverse medical reaction to products containing Naloxone. My 19 year old daughter has only had success on Subutex. Naloxone resulted in hives, rash, nausea, depression and a respiratory reaction requiring ER intervention. This mandate not only ignores established guidelines, it is punitive in nature in that patients who have followed protocol and have demonstrated success are being denied proven effective treatment. Any drug can be abused: this mandate is not going to assist or deter active addicts who are not invested in recovery. It will put the fragile recovery of many others at risk and denies physicians the right to use sound clinical judgement in continuing Bupe only protocols with patients who have demonstrated success and have documented sensitvity to Naloxone. A well intended law with potentially fatal outcomes.